FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210346055> ?p ?o ?g. }

• W4210346055 endingPage "362" @default.
• W4210346055 startingPage "362" @default.
• W4210346055 abstract "Epithelial ovarian cancer is the deadliest gynecological malignancy. The lack of effective treatments highlights the need for novel therapeutic interventions. The aim of this study was to investigate whether sustained adeno-associated virus (AAV) vector-mediated expression of vascular normalizing agents 3TSR and Fc3TSR and the antiangiogenic monoclonal antibody, Bevacizumab, with or without oncolytic virus treatment would improve survival in an orthotopic syngeneic mouse model of epithelial ovarian carcinoma. AAV vectors were administered 40 days post-tumor implantation and combined with oncolytic avian orthoavulavirus-1 (AOaV-1) 20 days later, at the peak of AAV-transgene expression, to ascertain whether survival could be extended. Flow cytometry conducted on blood samples, taken at an acute time point post-AOaV-1 administration (36 h), revealed a significant increase in activated NK cells in the blood of all mice that received AOaV-1. T cell analysis revealed a significant increase in CD8+ tumor specific T cells in the blood of AAV-Bevacizumab+AOaV-1 treated mice compared to control mice 10 days post AOaV-1 administration. Immunohistochemical staining of primary tumors harvested from a subset of mice euthanized 90 days post tumor implantation, when mice typically have large primary tumors, secondary peritoneal lesions, and extensive ascites fluid production, revealed that AAV-3TSR, AAV-Fc3TSR+AOaV-1, or AAV-Bevacizumab+AOaV-1 treated mice had significantly more tumor-infiltrating CD8+ T cells than PBS controls. Despite AAV-mediated transgene expression waning faster in tumor-bearing mice than in non-tumor bearing mice, all three of the AAV therapies significantly extended survival compared to control mice; with AAV-Bevacizumab performing the best in this model. However, combining AAV therapies with a single dose of AOaV-1 did not lead to significant extensions in survival compared to AAV therapies on their own, suggesting that additional doses of AOaV-1 may be required to improve efficacy in this model. These results suggest that vectorizing anti-angiogenic and vascular normalizing agents is a viable therapeutic option that warrants further investigation, including optimizing combination therapies." @default.
• W4210346055 created "2022-02-08" @default.
• W4210346055 creator A5001279470 @default.
• W4210346055 creator A5009859046 @default.
• W4210346055 creator A5028656647 @default.
• W4210346055 creator A5029977294 @default.
• W4210346055 creator A5038671554 @default.
• W4210346055 creator A5045071676 @default.
• W4210346055 creator A5046228493 @default.
• W4210346055 creator A5050599414 @default.
• W4210346055 creator A5056457864 @default.
• W4210346055 creator A5065619793 @default.
• W4210346055 creator A5066783121 @default.
• W4210346055 creator A5067227010 @default.
• W4210346055 creator A5070471447 @default.
• W4210346055 creator A5071283689 @default.
• W4210346055 creator A5083501904 @default.
• W4210346055 creator A5083693694 @default.
• W4210346055 creator A5083726052 @default.
• W4210346055 creator A5088839126 @default.
• W4210346055 creator A5089107486 @default.
• W4210346055 date "2022-02-02" @default.
• W4210346055 modified "2023-10-07" @default.
• W4210346055 title "AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma" @default.
• W4210346055 cites W1733011733 @default.
• W4210346055 cites W1769569140 @default.
• W4210346055 cites W1832925227 @default.
• W4210346055 cites W1940984680 @default.
• W4210346055 cites W1965535198 @default.
• W4210346055 cites W1969874649 @default.
• W4210346055 cites W1989896314 @default.
• W4210346055 cites W2008289270 @default.
• W4210346055 cites W2009041257 @default.
• W4210346055 cites W2016364569 @default.
• W4210346055 cites W2020280952 @default.
• W4210346055 cites W2022069273 @default.
• W4210346055 cites W2023061657 @default.
• W4210346055 cites W2023319852 @default.
• W4210346055 cites W2039941561 @default.
• W4210346055 cites W2041737674 @default.
• W4210346055 cites W2042633087 @default.
• W4210346055 cites W2042805311 @default.
• W4210346055 cites W2047911129 @default.
• W4210346055 cites W2053061515 @default.
• W4210346055 cites W2053706844 @default.
• W4210346055 cites W2055242813 @default.
• W4210346055 cites W2055515174 @default.
• W4210346055 cites W2055843476 @default.
• W4210346055 cites W2059243373 @default.
• W4210346055 cites W2070119976 @default.
• W4210346055 cites W2072771134 @default.
• W4210346055 cites W2074857354 @default.
• W4210346055 cites W2079150475 @default.
• W4210346055 cites W2079852644 @default.
• W4210346055 cites W2085939705 @default.
• W4210346055 cites W2086770058 @default.
• W4210346055 cites W2090364798 @default.
• W4210346055 cites W2090549613 @default.
• W4210346055 cites W2092932220 @default.
• W4210346055 cites W2094058129 @default.
• W4210346055 cites W2096951740 @default.
• W4210346055 cites W2104300873 @default.
• W4210346055 cites W2105665764 @default.
• W4210346055 cites W2111391096 @default.
• W4210346055 cites W2113122060 @default.
• W4210346055 cites W2114056376 @default.
• W4210346055 cites W2123291849 @default.
• W4210346055 cites W2131783235 @default.
• W4210346055 cites W2135947389 @default.
• W4210346055 cites W2139845843 @default.
• W4210346055 cites W2168202400 @default.
• W4210346055 cites W2233607944 @default.
• W4210346055 cites W2270542358 @default.
• W4210346055 cites W2313434580 @default.
• W4210346055 cites W2325875589 @default.
• W4210346055 cites W2593625946 @default.
• W4210346055 cites W2605456582 @default.
• W4210346055 cites W2766107001 @default.
• W4210346055 cites W2788948557 @default.
• W4210346055 cites W2789458710 @default.
• W4210346055 cites W2792485109 @default.
• W4210346055 cites W2797362195 @default.
• W4210346055 cites W2804543691 @default.
• W4210346055 cites W2811157611 @default.
• W4210346055 cites W2888640883 @default.
• W4210346055 cites W2909211125 @default.
• W4210346055 cites W2913977629 @default.
• W4210346055 cites W2916917493 @default.
• W4210346055 cites W2923832166 @default.
• W4210346055 cites W2943415606 @default.
• W4210346055 cites W2944519468 @default.
• W4210346055 cites W2946907202 @default.
• W4210346055 cites W2948715303 @default.
• W4210346055 cites W2954517372 @default.
• W4210346055 cites W3012467628 @default.
• W4210346055 cites W3041718992 @default.
• W4210346055 cites W3044122073 @default.
• W4210346055 cites W3125433041 @default.

• next